Major Events - Universal Medical (02666) plans to invest 15.03 million yuan to establish a joint venture that will create a collaborative platform integrating policy alignment, technology transfer, and clinical validation [1] - Fosun Pharma (02196) subsidiary has had its drug registration application for polyethylene glycol electrolyte solution accepted by the National Medical Products Administration [1] - China Biologic Products (01177) received approval from NMPA for the clinical trial application of LM-350 "CDH17 ADC" [1] - Xianruida Medical-B (06669) has received approval from the National Medical Products Administration for the registration of its coronary overall exchange balloon dilation catheter [1] - Meili Tianyuan Medical Health (02373) subsidiary plans to acquire medical and beauty assets related to Nairuier for 40 million yuan, adding 19 direct-operated stores [1] - China Tongru (01763) has exported its self-produced irradiation equipment to the Latin American market for the first time [1] Operating Performance - Trip.com Group-S (09961) reported a third-quarter net profit of 19.89 billion yuan, an increase of 194.01% year-on-year [1] - H&H International Holdings (01112) reported a 12.0% year-on-year increase in total revenue for the first three quarters [1] - Weibo-SW (09898) reported a net profit attributable to shareholders of 454 million USD for the third quarter, an increase of 55.43% year-on-year [1] - Baidu Group-SW (09888) reported total revenue of 31.2 billion yuan in the third quarter, with AI new business revenue growing over 50% year-on-year [1] - Xiaomi Group-W (01810) achieved a record adjusted net profit of 11.31 billion yuan in the third quarter, with smartphone shipments increasing year-on-year for nine consecutive quarters [1] - China Oriental Group (00581) reported sales of approximately 2.1 million tons of self-produced steel products in the third quarter [1] - BOSS Zhipin-W (02076) reported an adjusted net profit of approximately 999.2 million yuan in the third quarter, an increase of 34.2% year-on-year [1]

智通财经APP讯，先瑞达医疗-B(06669)发布公告，于2025年11月13日，集团收到中国国家药品监督管理 局对冠脉整体交换型球囊扩张导管井翼®的注册批准。井翼®适用于冠状动脉狭窄部位或冠状动脉旁路 血管狭窄部位进行球囊扩张，以改善心肌灌注，球囊直径为2.0-5.0mm的型号还适用于支架递送后扩 张。井翼®是一款半顺应性球囊扩张导管，凭借其更小的头端通过外径和球囊折叠外径，以及优化的推 送系统，实现了卓越的通过性和推送性，能有效应对慢性完全闭塞及严重钙化等复杂病变，其整体交换 设计也提升了手术效率与安全性。公司将适时在中国开展营销活动。 ...

格隆汇11月18日丨先瑞达医疗-B(06669.HK)公告，于2025年11月13日，集团收到中国国家药品监督管理 局对冠脉整体交换型球囊扩张导管井翼®的注册批准。井翼®适用于冠状动脉狭窄部位或冠状动脉旁路 血管狭窄部位进行球囊扩张，以改善心肌灌注，球囊直径为2.0-5.0mm的型号还适用于支架递送后扩 张。井翼是一款半顺应性球囊扩张导管，凭藉其更小的头端通过外径和球囊折叠外径，以及优化的推送 系统，实现了卓越的通过性和推送性，能有效应对慢性完全闭塞及严重钙化等复杂病变，其整体交换设 计也提升了手术效率与安全性。公司将适时在中国开展营销活动。 ...